Qiagen's Alacris Investment Provides Biomarker Pipeline for PCR-Based MDx Assay Panels

As part of its investment in Alacris, Qiagen receives an exclusive option to license biomarkers identified through the company's genomics data-analysis platform and develop them into PCR-based assays for use in molecular diagnostic and theranostic applications or biomedical research.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.